Zacks Small Cap Has Pessimistic View of ACHV FY2025 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – Investment analysts at Zacks Small Cap decreased their FY2025 earnings per share (EPS) estimates for Achieve Life Sciences in a research report issued on Monday, November 10th. Zacks Small Cap analyst J. Vandermosten now anticipates that the biopharmaceutical company will post earnings per share of ($1.23) for the year, down from their prior forecast of ($1.15). The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($1.17) per share. Zacks Small Cap also issued estimates for Achieve Life Sciences’ Q4 2025 earnings at ($0.24) EPS.

A number of other analysts have also issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Wednesday, November 5th. HC Wainwright assumed coverage on Achieve Life Sciences in a research note on Thursday, August 21st. They set a “buy” rating and a $12.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Achieve Life Sciences Stock Performance

Shares of NASDAQ ACHV opened at $4.77 on Wednesday. The company has a 50-day simple moving average of $3.72 and a 200-day simple moving average of $3.16. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.64 and a quick ratio of 6.64. The company has a market cap of $243.77 million, a PE ratio of -3.27 and a beta of 1.62. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $5.78.

Achieve Life Sciences (NASDAQ:ACHV) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04).

Insider Activity

In other news, insider Jaime Xinos sold 20,854 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $2.77, for a total transaction of $57,765.58. Following the completion of the sale, the insider directly owned 74,432 shares in the company, valued at $206,176.64. This represents a 21.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Thomas Braxton King sold 139,858 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $2.77, for a total value of $387,406.66. Following the completion of the transaction, the director directly owned 315,142 shares in the company, valued at $872,943.34. This trade represents a 30.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 381,972 shares of company stock valued at $1,084,997 in the last ninety days. 3.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. raised its holdings in shares of Achieve Life Sciences by 81.3% in the 2nd quarter. Franklin Resources Inc. now owns 4,459,014 shares of the biopharmaceutical company’s stock worth $10,077,000 after purchasing an additional 2,000,079 shares during the period. Vanguard Group Inc. increased its position in Achieve Life Sciences by 14.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company’s stock worth $7,755,000 after purchasing an additional 311,925 shares in the last quarter. Simplify Asset Management Inc. increased its position in Achieve Life Sciences by 443.7% during the 2nd quarter. Simplify Asset Management Inc. now owns 1,184,512 shares of the biopharmaceutical company’s stock worth $2,677,000 after purchasing an additional 966,667 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in Achieve Life Sciences in the second quarter valued at approximately $2,652,000. Finally, Nantahala Capital Management LLC lifted its position in Achieve Life Sciences by 37.4% during the first quarter. Nantahala Capital Management LLC now owns 898,885 shares of the biopharmaceutical company’s stock valued at $2,400,000 after buying an additional 244,885 shares in the last quarter. 33.52% of the stock is currently owned by institutional investors and hedge funds.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.